Detalhe da pesquisa
1.
Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.
Cancer;
118(22): 5709-18, 2012 Nov 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22786751
2.
Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
Respir Med;
132: 31-41, 2017 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29229103
3.
The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given 'as needed' in mild asthma: study protocols for two randomised controlled trials.
Trials;
18(1): 12, 2017 01 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28069068
4.
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
Lancet;
366(9496): 1527-37, 2005.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16257339
5.
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
J Clin Oncol;
31(14): 1740-7, 2013 May 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23569308
6.
A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer.
Cancer Chemother Pharmacol;
67(5): 1203-8, 2011 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21153822
7.
Analysis of duration of response in oncology trials.
Contemp Clin Trials;
29(4): 456-65, 2008 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18187370
8.
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
Anticancer Drugs;
17(4): 401-9, 2006 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16549997